Cerebras IPO targets up to $26.6B valuation

Strip away the wafer-scale marketing and the cleanest way to read the Cerebras prospectus is this: OpenAI is simultaneously its biggest customer, one of its biggest creditors, and — through its executives' personal angel checks — an early insider. The January 2026 Master Relationship Agreement commits OpenAI to up to 750 megawatts of Cerebras inference capacity through 2028, a contract sized at more than $20 billion. On top of that, OpenAI has loaned Cerebras $1 billion, secured by warrants on more than 33 million shares — a structure that effectively gives OpenAI an option to convert lender status into one of the largest equity stakes in the company if Cerebras stumbles. Sam Altman and other OpenAI executives also hold personal angel positions from the early rounds.

That triple-overlap is what re-opened the IPO window. The 2024 attempt died because revenue was concentrated in one Gulf customer (G42) that CFIUS would not bless; the 2026 attempt works because revenue is now concentrated in a different partner — OpenAI — that Washington has no objection to. But the concentration itself didn't go away; only its citizenship did. On Reddit, the most-circulated framing was that Altman's personal stake plus OpenAI's $10B-and-growing order book reads as a closed loop: the buyer of the chips is also funding the buyer of the chips. Bull case: "OpenAI doubled their $10B order pretty quickly. That's a pretty great sign that their chips work." Bear case from the same threads: same fact, opposite sign — when a customer this entangled is your validation, the validation is harder to read.

At the top of the range, Cerebras prices at roughly $26.6 billion on $510 million of FY2025 revenue — about 70 times trailing sales. Nvidia, the company Cerebras is pitched against, trades around 23x. The bull argument for the premium is simple: Cerebras grew revenue ~75% year-over-year (from $290.3M in FY2024), swung to a positive net income with $1.38 EPS versus a prior $9.90 loss, and just signed a multi-year contract larger than its entire historical revenue base. At those growth rates, last year's multiple is the wrong denominator.

The bear argument lives in two specific operational facts that the prospectus itself flags. First, every Cerebras chip is a full silicon wafer — one piece of silicon roughly the size of a dinner plate, instead of being cut into thousands of smaller GPUs. That design is what delivers the headline 1,800 tokens/sec on Llama 3.1 8B versus ~90 on Nvidia (a ~20x speedup), but it also means yield is inherently harder than a normal chip — a single bad region can compromise an entire wafer — and only TSMC can make it. There is no second source. Second, the OpenAI deal commits Cerebras to 750 megawatts of capacity by 2028, a scale-up the company has never attempted. Adam Levy's published view is that 70x sales does not yet price either of those risks: "the price and execution risk will keep me from buying into the IPO." The IPO is essentially a bet that wafer-scale yield, TSMC capacity allocation, and data-center buildout all go right at once.

Cerebras's pitch leans on raw inference speed, and the numbers are real — roughly 20x Nvidia on Llama 3.1 8B by the company's own measurement. But the dominant counter-thread in technical communities discussing the deal isn't "is the chip fast?" It's "can a non-Nvidia chip even be adopted at scale?" The framing that recurred across Reddit threads was a one-liner: chips win benchmarks, ecosystems win customers. CUDA — Nvidia's software stack that almost every AI training and inference codebase has been written against for a decade — is the moat that doesn't appear on a tokens-per-second chart.

IPOX's Lukas Muehlbauer captured the optimistic version: Nvidia stays dominant, but "there is room for specialist chip companies if they can offer clear speed or cost advantages." The OpenAI deal is the exact specialist niche he's describing — fast inference for a single demanding workload, where porting cost is paid once and recouped over 750 MW of usage. The skeptics' read is that this is precisely why the OpenAI contract is load-bearing: outside of customers large enough to justify rewriting their stack, the CUDA gravity well still pulls everyone back. A second hyperscaler win — AWS has been named as a target — is what would convert Cerebras from "OpenAI's fast-inference vendor" into a platform. Without it, the chip is excellent and the business is one renegotiation away from trouble.

It's worth being specific about what changed between the 2024 IPO that died and the 2026 IPO that's oversubscribed, because the popular framing — "Cerebras finally got its act together" — gets the mechanism wrong. In H1 2024, roughly 87% of revenue came from G42, an Abu Dhabi-based AI company with minority Chinese investors. CFIUS opened a national-security review in October 2024 and the IPO was shelved. The review wrapped on March 31, 2025 only after G42 divested its Chinese positions and converted its Cerebras stake to non-voting shares. By then, Cerebras's revenue mix had already started shifting — and in January 2026 it shifted decisively when OpenAI signed for 750 MW.

So the structural change isn't that customer concentration was solved. It's that the concentrated customer was swapped for one that doesn't trigger a U.S. national-security review. From a regulatory perspective, that's everything. From a business-risk perspective, it's a different question: Cerebras is still a single-large-customer company, and that customer now also holds warrants on tens of millions of shares. The most-shared X framing of the sequence — Altman invests personally, then OpenAI signs $10B, then Cerebras refiles — is a clean narrative because it is, mechanically, the actual sequence. The 2026 IPO is the 2024 IPO with the geopolitical risk removed and the commercial concentration deepened.

Beyond Cerebras itself, the deal matters because there isn't much else to look at. Tech IPOs started 2026 softly, and the queue behind Cerebras includes a much larger AI-adjacent name (SpaceX, with Starlink) plus a handful of infrastructure plays watching for a price signal. A $10B order book against $3.5B of stock isn't subtle — it says public-market investors who have been waiting on the sidelines for an AI-infrastructure name they could actually buy are willing to write checks at 70x sales when the growth story is anchored to OpenAI.

Muehlbauer's framing — that this is "an important signal deal for the IPO market as a test of whether public investors are ready to fund high-growth AI infrastructure companies after a softer start to the year" — is the read that bankers across the rest of the pipeline will be running their own pricing committees against. The honest open question is what happens at the second derivative. If CBRS prints above range and trades up, the next set of AI-infra issuers will price aggressively and the multiple gets normalized. If it prices in range but trades flat or down, the message is that the public market wants AI exposure but not at private-market valuations — which would re-open the conversation about late-stage AI rounds priced for perfection. The week of May 11 is the data point everyone in that conversation is waiting on.